PlantForm Corporation

04/23/2024

We'll be at the International Society for Plant Molecular Farming (ISPMF) Conference in Cape Town, South Africa May 6-8!

David Cayea, our Chief Operating Officer, will engage in strategic meetings at the conference to advance R&D collaborations using PlantForm Corporation's vivoXPRESS platform for sustainable, plant-based biopharmaceutical manufacturing. 🌿

Thank you to Innovation Trade Commissioner Service - Global Affairs Canada for supporting our work to forge new partnerships that bring Canadian biotech innovation to the world!

01/18/2024

Exciting news! PlantForm Corporation and 3DBiofibr have been awarded $1.3M in NGen funding to advance recombinant human collagen fiber manufacturing technology.

The project aims to develop world’s first scalable dry spinning of recombinant human collagen for use in a broad range of sectors including regenerative medicine.

Read more here:

Project leverages partners’ strengths to develop world’s first scalable dry spinning of recombinant human collagen for use in a broad range of sectors including regenerative medicine

12/06/2023

New article in BioProcess International about our work to leverage plant-based protein-expression systems for biodefense applications!

Read the article to learn about:
- ricin as a biosecurity threat
- the utility of mAb-based bioterrorism countermeasures
- the role that plants play in developing such therapeutics
- how plant-based systems enable flexible, high-yield, and low-cost manufacturing of proteins with the requisite glycosylation profiles
- how drug developers have overcome many of the technical and regulatory concerns that hampered initial research into plant-system protein expression
- the need for investment in manufacturing infrastructure, specifically large-scale biomanufacturing capacity.

Plant-based protein expression research is active in therapeutics development for bioterrorism mitigation and biodefense applications.

08/29/2023

PlantForm has 2 immediate job openings!
1️⃣ Biotechnology Technician (Guelph or Bolton, ON).
2️⃣ Research Associate 1 (Bolton, ON).

See the full job descriptions here: https://www.plantformcorp.com/careers.aspx

03/28/2023

Signing ceremony in Brazil to mark PlantForm Corporation and Bio-Manguinhos/Fiocruz's agreement to co-develop a biosimilar pembrolizumab for lung cancer using PlantForm's plant-based vivoXPRESS manufacturing system.

03/20/2023

Press Release: PlantForm and UBC researcher receive GlycoNet funds to develop novel treatment for Type-2 diabetes

GUELPH, Ont., CANADA, March 20, 2023 — PlantForm Corporation has teamed up with a University of British Columbia research group led by Dr. Joerg Bohlmann to develop a novel plant-based treatment option for Type-2 diabetes and obesity, with support from GlycoNet (Canadian Glycomics Network).

03/07/2023

We're pleased to announce that PlantForm Corporation and Bio-Manguinhos/Fiocruz have signed a new agreement to develop a pembrolizumab cancer drug and up to 5 future products for the Brazilian and other world markets.

Pembrolizumab is widely used alone or in combination with other drugs to treat a variety of cancers including certain types of breast cancer, skin cancer (including melanoma), non-small cell lung cancer and more than a dozen other types.

Read the full press release:

GUELPH, Ont., CANADA, March 7, 2023 — Canadian biopharmaceutical innovator PlantForm Corporation and Bio-Manguinhos / Fiocruz (Health Ministry of Brazil) have signed a collaborative research and development agreement to develop a biosimilar pembrolizumab and up to five future products for the Braz...

02/27/2023

PRESS RELEASE: U.S. Patent Granted for Made-in-Canada Ricin Antibody Technology

The U.S. Patent Office has granted a patent for a plant-based manufacturing process to produce an antibody for treatment of ricin exposure, an outcome of research and development by AntoXa Corporation under contract with Defence Research and Development Canada (DRDC), an Agency of the Canadian Department of National Defence.

AntoXa, a wholly-owned subsidiary of PlantForm Corporation, has an exclusive license from DRDC to develop and produce the PhD9 monoclonal antibody treatment in plants for sale in markets worldwide.

Read the full press release:

GUELPH, Ont., CANADA, Feb. 27, 2023 — The U.S. Patent Office has granted a patent for a plant-based manufacturing process to produce an antibody for treatment of ricin exposure, an outcome of research and development by AntoXa Corporation under contract with Defence Research & Development Canada (...

12/21/2022

Good news for Ontario: the provincial government is introducing a new policy that requires less expensive versions of biologic drugs to be offered to patients.

Under the new policy, there will be a nine-month transition period that is set to start March 31.

The mandatory switching policy - already adopted in B.C. and Alberta - will save money and better ensure the long-term sustainability of the province’s drug plan, according to a government official

11/17/2022

PlantForm Corporation has received a U.S. patent for our line of fast-growing transgenic plants!

GUELPH, Ont., November 17, 2022 —PlantForm Corporation announced today that the U.S. Patent Office has granted a patent for the Company’s bespoke line of Nicotiana benthamiana plants used to produce monoclonal antibodies, therapeutic proteins and vaccines.

11/01/2022

Our thanks to the Grand River Agricultural Society for supporting our travel to 2022 to discuss regional and global partnering opportunities for PlantForm’s animal health programs.

PlantForm's animal health solutions include the world’s first plant-based vaccine for Classical Swine Fever and an edible antibody that prevents E.coli infection in pigs.